Cargando…
Disease-modifying targets in neurodegenerative disorders : paving the way for disease-modifying therapies /
Disease-Modifying Targets in Neurodegenerative Disorders: Paving the Way for Disease-Modifying Therapies examines specific neurodegenerative disorders in comprehensive chapters written by experts in the respective fields. Each chapter contains a summary of the disease management field, subsequently...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
London :
Academic Press,
[2017]
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Ii 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn981463382 | ||
| 003 | OCoLC | ||
| 005 | 20231120112223.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 170405s2017 enka ob 001 0 eng d | ||
| 010 | |a 2016960656 | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d IDEBK |d EBLCP |d N$T |d YDX |d OPELS |d OCLCF |d MERER |d UPM |d OCLCQ |d OTZ |d OCLCQ |d CASUM |d OCLCQ |d OCLCO |d OCLCA |d D6H |d DKU |d OCLCQ |d U3W |d OCLCA |d IAY |d AU@ |d WYU |d OCLCA |d OCLCQ |d VT2 |d OCLCO |d OCLCQ |d UKMGB |d OCLCQ |d OCLCO |d S2H |d OCLCO |d LVT |d OCLCA |d OCLCO |d OCLCQ |d SFB | ||
| 066 | |c (S | ||
| 015 | |a GBB763363 |2 bnb | ||
| 016 | 7 | |a 018288712 |2 Uk | |
| 019 | |a 981616466 |a 981847821 |a 1006303310 |a 1007069940 |a 1011181914 |a 1066629511 |a 1229440477 |a 1235834939 | ||
| 020 | |a 9780128052662 |q (electronic bk.) | ||
| 020 | |a 012805266X |q (electronic bk.) | ||
| 020 | |z 9780128051207 | ||
| 020 | |z 0128051205 | ||
| 035 | |a (OCoLC)981463382 |z (OCoLC)981616466 |z (OCoLC)981847821 |z (OCoLC)1006303310 |z (OCoLC)1007069940 |z (OCoLC)1011181914 |z (OCoLC)1066629511 |z (OCoLC)1229440477 |z (OCoLC)1235834939 | ||
| 050 | 4 | |a RC349.8 | |
| 060 | 4 | |a WL 358.5 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.8046 |2 23 |
| 245 | 0 | 0 | |a Disease-modifying targets in neurodegenerative disorders : |b paving the way for disease-modifying therapies / |c edited by Veerle Baekelandt, Evy Lobbestael. |
| 264 | 1 | |a London : |b Academic Press, |c [2017] | |
| 264 | 4 | |c �2017 | |
| 300 | |a 1 online resource : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |6 880-01 |a Cover; Title Page; Copyright Page; Contents; List of Contributors; Chapter 1 -- The multitude of therapeutic targets in neurodegenerative proteinopathies; Protein Misfolding and Aggregation; Mechanism of Assembly; Prion-Like Propagation of Protein Assemblies; Propagation Routes of Pathogenic Protein Aggregates; Limiting Steps in the Propagation of Pathogenic Protein Assemblies; Therapeutic Strategies Targeting the Physiological Levels of Aggregation-Prone Proteins Involved in Neurodegeneration. | |
| 505 | 8 | |a Therapeutic Strategies Targeting the Misfolding and Aggregation of Proteins Involved in NeurodegenerationTherapeutic Strategies Targeting the Accumulation of Misfolded Pathologic Protein Aggregates; Therapeutic Strategies Targeting the Cell-to-Cell Propagation of Pathogenic Protein Aggregates; Therapeutic Strategies Aimed at Restoring the Damage Pathogenic Protein Aggregates Induce; Therapeutic Strategies Targeting Misfolded Pathologic Protein Aggregate-Mediated Neuroinflammation; Limitations of the Different Therapeutic Strategies; Acknowledgments; References. | |
| 505 | 8 | |a Mechanisms of Neuroinflammation-Mediated NeurodegenerationAlzheimer's Disease; Parkinson's Disease; Amyotrophic Lateral Sclerosis; Huntington's Disease; Frontotemporal Dementia and Lewy Body Dementia; Therapeutic Strategies Targeting Neuroinflammation in Progressive Neurodegenerative Diseases; Future Perspectives; Conclusions; References; Chapter 4A -- Stem cells in neurodegeneration: mind the gap; Introduction; Part I: Stem Cells; Genome Editing of Stem Cells; The Generation of Specific Cell Types; Part II: Stem Cells as Regenerative Therapy; Clinical Translation and Immunology. | |
| 588 | 0 | |a Vendor-supplied metadata. | |
| 520 | 2 | |a Disease-Modifying Targets in Neurodegenerative Disorders: Paving the Way for Disease-Modifying Therapies examines specific neurodegenerative disorders in comprehensive chapters written by experts in the respective fields. Each chapter contains a summary of the disease management field, subsequently elaborating on the molecular mechanisms and promising new targets for disease-modifying therapies. This overview is ideal for neuroscientists, biomedical researchers, medical doctors, and caregivers, not only providing readers with a summary of the way patients are treated today, but also offering a glance at the future of neurodegenerative disorder treatment. This book provides a comprehensive overview of how key proteins in neurodegenerative disorders can be used as targets to modify disease progress and summarizes how patients are treated today, providing a glance at future disease management. This book includes intelligible and informative information that is perfect for non-specialists, medical practitioners, and scientists. | |
| 650 | 0 | |a Nervous system |x Diseases |x Treatment. | |
| 650 | 0 | |a Nervous system |x Degeneration. | |
| 650 | 2 | |a Neurodegenerative Diseases |x therapy |0 (DNLM)D019636Q000628 | |
| 650 | 6 | |a Syst�eme nerveux |0 (CaQQLa)201-0007359 |x Maladies |0 (CaQQLa)201-0007359 |x Traitement. |0 (CaQQLa)201-0377521 | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Nervous system |x Degeneration. |2 fast |0 (OCoLC)fst01036090 | |
| 650 | 7 | |a Nervous system |x Diseases |x Treatment. |2 fast |0 (OCoLC)fst01036124 | |
| 655 | 0 | |a Electronic books. | |
| 655 | 4 | |a Internet Resources. | |
| 700 | 1 | |a Baekelandt, Veerle, |e editor. | |
| 700 | 1 | |a Lobbestael, Evy, |e editor. | |
| 776 | 0 | 8 | |i Print version: |t Disease-modifying targets in neurodegenerative disorders. |d London : Academic Press, [2017] |z 0128051205 |z 9780128051207 |w (OCoLC)960902043 |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780128051207 |z Texto completo |
| 880 | 8 | |6 505-00/(S |a Chapter 2 -- Synuclein misfolding as a therapeutic targetIntroduction; The Conformational Landscape of α-Synuclein: the Native State; Cytosolic Folding States; Membrane-Bound Folding States; The Conformational Landscape of α-Synuclein: Misfolded Variants; Folding Intermediates; Oligomeric Variants; Fibrillar Variants; Misfolding in Complex Environments; Synuclein Strains; Glycation of α-SYN-an Age-Associated Posttranslational Modification; Misfolding of α-Synuclein as a Therapeutic Target; Preserving the Native State; Preventing the Formation of Folding Intermediates; Targeting Aggregation. | |
| 880 | 8 | |6 505-01/(S |a Lowering α-synuclein expression levelsDirect inhibition of α-synuclein aggregation; Stabilizing Membrane Interactions; Conclusions; References; Chapter 3 -- Neuroinflammation as a therapeutic target in neurodegenerative diseases; Introduction; The Global Burden of Neurodegenerative Diseases and the Challenge of Developing Effective Therapeutics; Glial Cells in CNS Development, Homeostasis, and Pathology; Microglia; Astrocytes; Oligodendrocytes and Ependymal Cells; Chronic Neuroinflammation as a Common Pathophysiological Mediator in Progressive Neurodegenerative Diseases. | |